On March 10, 2025, Cuu Long Pharmaceutical Joint Stock Company successfully organized the EU-GMP seminar with the theme “Expert Consultation – Practical Dialogue”. This special event brought together leading experts from Vietnam and India to share experiences, discuss, and propose practical solutions for Cuu Long Pharmaceutical in the process of building and applying EU-GMP standards.
Attending the event were Mr. Nguyen Van Ban – General Director of F.I.T Group; Ms. Nguyen Thi Thu Huong – General Director of Benovas Pharmaceutical JSC and Assistant to the Chairman of the Board of Directors; Mr. Nguyen Trong Duc – Deputy General Director of Production & Maintenance at Cuu Long Pharmaceutical; Mr. Nguyen Ba The – Business Development Director; and Mr. Do Minh Si – concurrently serving as Technical Director (QA, QC, R&D). The expert delegation was led by Mr. Dao Xuan Huong – Chairman of the Board of Directors of GMPC Vietnam JSC, while the Indian expert delegation was headed by Mr. Rohit Ochaney – Co-founder and CEO of Inotek India.
The seminar was divided into two sessions: listening to expert consultation and practical dialogue. This was an opportunity for Cuu Long Pharmaceutical to exchange knowledge about EU-GMP with leading experts, gaining deeper insights into challenges, opportunities, and effective solutions for investing in and building EU-GMP standard factories.
The program also focused on discussing the necessary procedures to achieve EU-GMP certification, ensuring the quality and competitiveness of Cuu Long Pharmaceutical’s products in the market.
“Today’s seminar is also an occasion for us to connect and share real-world experiences, creating a solid foundation for the sustainable development of the pharmaceutical manufacturing industry. At the same time, it promotes the transition and quality improvement of products, effectively meeting international standards,” said Ms. Nguyen Thi Thu Huong – General Director of Benovas Pharmaceutical JSC and Assistant to the Chairman of the Board of Directors, responsible for internal operations at Cuu Long Pharmaceutical.
Ms. Nguyen Thi Thu Huong Speaks at the Event
The seminar was structured into two sessions under two main topics: Expert Consultation and Practical Dialogue. In the first session, Mr. Rohit Ochaney – Co-founder and CEO of Inotek India – gave a presentation answering the question: *”Why is adopting EU-GMP standards an essential factor in the 21st-century pharmaceutical industry?”. He deeply analyzed why EU-GMP standards are not merely a quality requirement but a key factor in enhancing the competitiveness of pharmaceutical companies in the global market.
With the rapid development of technology and the growing demand for product quality, EU-GMP standards not only help pharmaceutical companies achieve superior product quality but also build strong trust among consumers and regulatory authorities. “In today’s globalized world, adopting EU-GMP is not just a mandatory requirement for exporting products to strict markets like the EU. It is also a crucial factor that helps pharmaceutical companies increase their competitiveness and expand their international market share,” Mr. Rohit Ochaney shared.
The long-term benefits that businesses can gain from maintaining EU-GMP standards include risk minimization, optimization of production processes, and ensuring pharmaceutical safety for consumers. According to Mr. Ochaney, pharmaceutical companies must comply with these standards not only to meet legal requirements but also to build a sustainable development strategy that enables them to stand firm in an increasingly competitive market.
He also provided real-world examples from Inotek’s experiences and projects, helping businesses gain a clearer understanding of the challenges and opportunities in adopting EU-GMP standards.
Mr. Rohit Ochaney – Indian Expert – Shares the Importance of EU-GMP Standards in the 21st Century Pharmaceutical Industry
Also at the seminar, Mr. Dao Xuan Huong – Chairman of the Board of Directors of GMPC Vietnam JSC – passionately shared his practical experiences in investing and building EU-GMP standard factories in Vietnam. With years of expertise, he provided deep insights into key phases of factory construction, from site selection and facility design to equipping modern production lines that strictly adhere to quality standards.
The second session of the seminar impressed participants with a roundtable discussion, featuring two experts, Dao Xuan Huong and Rohit Ochaney, along with two specialists from Cuu Long Pharmaceutical: Mr. Do Minh Si – Technical Director (QA, QC, R&D) and Mr. Mai Khac Tung – Assistant to the Chairman of the Board of Directors.
Expert Do Minh Si Shares Insights at the Seminar
Experts from QA, QC, R&D, and Investment Management departments directly discussed with the four experts various topics, including: ensuring a robust quality management system; meeting quality control requirements across the entire production chain; exploring new methods and technologies to improve accuracy in product quality inspection; developing new products that fully comply with EU-GMP standards; constructing and upgrading factory infrastructure to meet EU-GMP requirements
After four hours of discussion, the seminar provided comprehensive and concrete solutions to address challenges in implementing and maintaining EU-GMP standards. It also served as an opportunity for Cuu Long Pharmaceutical and expert delegations to exchange experiences in applying EU-GMP standards, strengthening collaboration between parties, and paving the way for new directions in enhancing competitiveness and sustainable development.
The Seminar Demonstrates Cuu Long Pharmaceutical’s Commitment to Achieving EU-GMP Standards
With the knowledge and solutions shared during the seminar, Cuu Long Pharmaceutical has strengthened its ability to build and maintain an EU-GMP standard factory, meeting quality requirements. Step by step, the company is realizing its vision of becoming Vietnam’s most highly regarded pharmaceutical company among patients, partners, and employees through innovative, accessible, and high-quality healthcare products and services.
